Recently, Yunnan Watson BioYuxi Watson Biotechnology Co. , Ltd., a subsidiary of Watson Biotechnology Co., Ltd. (hereinafter referred to as " Watson Biotechnology " ), and Pharmaniaga Lifescience Sdn. Bhd. (hereinafter referred to as "PLS"), a wholly-owned subsidiary of Pharmaniaga Berhad of Malaysia, have officially signed an agreement for the distribution and localized production of the 13-valent pneumococcal polysaccharide conjugate vaccine (hereinafter referred to as "13-valent pneumococcal conjugate vaccine" or "PCV-13") in Malaysia. Under the agreement, PLS will serve as Watson Biotechnology's partner in Malaysia, jointly promoting technology transfer, localized production, and commercialization of PCV-13.

After in-depth business negotiations and technical exchanges, Watson Bio and PLS reached a consensus on core terms such as cooperation model and technology implementation path, and ultimately facilitated the signing of this cooperation agreement.

PCV-13 effectively prevents invasive diseases caused by pneumococci, including pneumonia, meningitis, and bacteremia, providing critical protection for infants and children under six years old, particularly against drug-resistant pneumococci. Malaysia has approximately 500,000 newborns annually. According to Ministry of Health procurement data, the annual demand for PCV vaccine is approximately 1.5 million doses, indicating stable market demand. This localized collaboration will meet vaccine needs in Malaysia and the region, significantly improving the stability and accessibility of vaccine supply and ensuring that more children receive safe and effective immunization in a timely manner.

This collaboration is a key achievement in Watson Biopharma's strategy to expand its Chinese pharmaceutical business overseas. It also marks the company's sixth localized collaboration for its 13-valent pneumococcal conjugate vaccine, following projects in Morocco, Indonesia, Egypt, Mexico, and Bangladesh. Furthermore, this collaboration was facilitated by Dubai-based RevonBioFZ-LLC, leveraging its network of resources.

Source：https://finance.eastmoney.com/a/202510273545504241.html